Enasidenib mesylate is the mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2). It is used as an active pharmaceutical ingredient in the manufacturing of pharmaceutical formulations.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Enasidenib mesylate?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Enasidenib
pharmaceutical raw material
Bendamustine
pharmaceutical raw material
25-cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)avermectin A1a
pharmaceutical raw material
Linezolid
pharmaceutical raw material
Zoledronic acid monohydrate
pharmaceutical raw material
methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
ORZHZQZYWXEDDL-UHFFFAOYSA-N
CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O
Sourcing Enasidenib mesylate?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.